Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

New England Journal of Medicine

Volumn 331, Issue 9, 1994, Pages 567-573

  Brittenham, Gary M ^a   Griffith, Patricia M ^d   Nienhuis, Arthur W ^c   McLaren, Christine E ^b   Young, Neal S ^d   Tucker, Eben E ^e   Allen, Christopher J ^a   Farrell, David E ^a   Harris, John W ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b MINNESOTA STATE UNIVERSITY MOORHEAD   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d Hematology Branch   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; FERRITIN; GLUCOSE; IRON;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; EDEMA; FEMALE; HEART DISEASE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INJECTION PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INTRAVENOUS DRUG ADMINISTRATION; IRON CHELATION; IRON OVERLOAD; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CONFIDENCE INTERVALS; DEFEROXAMINE; FEMALE; HUMANS; IRON; LIVER; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME;

EID: 0028059813     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199409013310902     Document Type: Article

References (32)

1. Brittenham GM. The red cell cycle. In: Brock J, Halliday J, Pippard M, Powell L, eds. Iron metabolism in health and disease. Philadelphia: W.B. Saunders, 1994:31-62.
2. Modell B, Berdoukas V. The clinical approach to thalassemia. New York: Grune & Stratton, 1984.
3. Barry M, Flynn DM, Letsky EA, Risdon RA Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. BMJ 1974; 2:16-20
4. Sephton Smith R Iron excretion in thalassaemia major after administration of chelating agents. BMJ 1962; 2:1577-1580
5. Brittenham GM Development of iron-chelating agents for clinical use. Blood 1992; 80:569-574
6. Propper RD, Shurin SB, Nathan DG Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med 1976; 294:1421-1423
7. Propper RD, Cooper B, Rufo RR, Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 1977; 297:418-423
8. Cohen A, Martin M, Schwartz E Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 1984; 58:369-373
9. Freeman AP, Giles RW, Berdoukas VA, Talley PA, Murray IP Sustained normalization of cardiac function by chelation therapy in thalassaemia major. Clin Lab Haematol 1989; 11:299-307
10. Wolfe L, Olivieri N, Sallan D, Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985; 312:1600-1603
11. De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F Insulin dependent diabetes in thalassaemia. Arch Dis Child 1988; 63:58-62
12. Fosburg MT, Nathan DG Treatment of Cooley's anemia. Blood 1990; 76:435-444
13. Piomelli S Management of Cooley's anaemia. Baillieres Clin Haematol 1993; 6:287-298
14. Borgna-Pignatti C, De Stefano P, Zonta L, Growth and sexual maturation in thalassemia major. J Pediatr 1985; 106:150-155
15. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ Effect of age at the start of iron chelation therapy on gonadal function in β-thalassemia major. N Engl J Med 1990; 323:713-719
16. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr 1991; 118:540-545
17. Zurlo MG, De Stefano P, Borgna-Pignatti C, Survival and causes of death in thalassaemia major. Lancet 1989; 2:27-30
18. Marcus RE, Davies SC, Bantock HM, Underwood SR, Walton S, Huehns ER Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major. Lancet 1984; 1:392-393
19. Brittenham GM, Farrell DE, Harris JW, Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982; 307:1671-1675
20. Brittenham GM Noninvasive methods for the early detection of hereditary hemochromatosis. Ann N Y Acad Sci 1988; 526:199-208
21. Brittenham GM, Cohen AR, McLaren CE, Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993; 42:81-85
22. Pootrakul P, Kitcharoen K, Yansukon P, The effect of erythroid hyperplasia on iron balance. Blood 1988; 71:1124-1129
23. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981.
24. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
25. Peto R, Pike MC, Armitage P, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35:1-39
26. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980:740-2.
27. Cox DR Regression models and life-tables. J R Stat Soc [B] 1972; 34:187-220
28. Schoenfeld D Partial residuals for the proportional hazards regression model. Biometrika 1982; 69:239-241
29. Cohen A, Martin M, Mizanin J, Konkle DF, Schwartz E Vision and hearing during deferoxamine therapy. J Pediatr 1990; 117:326-330
30. Freedman MH, Grisaru D, Olivieri N, MacLusky I, Thorner PS Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. Am J Dis Child 1990; 144:565-569
31. Pippard MJ Measurement of iron status. Prog Clin Biol Res 1989; 309:85-92
32. Lucarelli G, Galimberti M, Polchi P, Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993; 329:840-844